May 17, 2017
The health ministry’s key reimbursement panel on May 17 gave the thumbs-up to Takeda Pharmaceutical’s multiple myeloma (MM) drug Ninlaro (ixazomib) and seven other drugs (APIs) for their NHI reimbursement price listing on May 24, with their launches expected soon...read more